In the Alzheimer’s affected brain, abnormal levels of the beta-amyloid protein clump together to form plaques (seen in brown) that collect between neurons and disrupt cell function. Abnormal collections of the tau protein accumulate and form tangles (seen in blue) within neurons, harming synaptic communication between nerve cells. Image by National Institute on Aging, NIH via Flickr. Public domain photo
On June 1, Medicare officials announced plans to cover new FDA-approved drugs that may slow the progression of Alzheimer’s disease. The Centers for Medicare and Medicaid Services would also require patients using the drugs to register for the purpose of gathering information on treatment results.
